At the news
? BULLISHIMPACT 7/10 8-K filed Jun 12, 2026 at 07:00 ET
Dianthus Therapeutics posted an updated corporate presentation disclosing a 75% confirmed responder rate from the first 40 patients completing Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP. The data supports an early GO decision and a streamlined trial design with ~1/3 fewer Part B patients, with Part B top-line guidance expected by YE'26. The filing also reiterates upcoming catalysts: Ph. 3 gMG EMERGE initiation (mid-'26), Ph. 2 MMN MoMeNtum data (Q4'26), and Ph. 1 DNTH212 data (2H'26).
- 75% confirmed responder rate (30 of 40) in Part A of CAPTIVATE Ph. 3 CIDP trial, exceeding the 50% threshold for GO decision
- CAPTIVATE trial design streamlined: Part B reduced from 192 to 128 patients, Part A enrollment capped at 256 vs. 480
- No related serious infections, no clinical symptoms of DIL, no related SAEs or discontinuations in interim analysis
- Cash position of ~$1.2B as of March 31, 2026, with runway into 2030
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access